This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Encompass Health (EHC) Stock Down 6% Despite Q2 Earnings Beat
by Zacks Equity Research
Encompass Health's (EHC) Q2 results reflect improved net patient revenue per discharge, partly offset by higher costs. It currently estimates 2024 adjusted EPS within $3.97-$4.22, up from the earlier view of $3.86-$4.11.
Humana (HUM) Q2 Earnings Beat on Medicare Advantage Strength
by Zacks Equity Research
Humana's (HUM) second-quarter results reflect overall premium growth and a well-performing CenterWell unit, partly offset by elevated costs. It expects individual MA membership to record growth of 225,000 in 2024.
Compared to Estimates, Humana (HUM) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Humana (HUM) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Humana (HUM) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 18.17% and 2.61%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Humana (HUM) Navigate Rising Expenses in Q2 Earnings?
by Zacks Equity Research
Humana's (HUM) second-quarter results are expected to be impacted by declining Stand-Alone PDPs and total Specialty Medical membership levels.
Insights Into Humana (HUM) Q2: Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Humana (HUM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Centene (CNC) Q2 Earnings Miss Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of -0.82% and 9.10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cigna (CI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molina (MOH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 2.27% and 0.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Humana (HUM) Q2 Earnings Expected to Decline
by Zacks Equity Research
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Select Medical's (SEM) Unit Begins IPO Roadshow for 22.5M Shares
by Zacks Equity Research
Select Medical's (SEM) subsidiary, Concentra, starts roadshow for IPO of 22.5 million shares, aiming to list on the NYSE under ticker "CON" with an expected price range of $23-$26 per share.
UnitedHealth Group (UNH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 2.26% and 0.15%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth (UNH) Pre-Q2 Earnings: Healthy Buy or a Wait-&-See?
by Kaibalya Pravo Dey
UnitedHealth's (UNH) second-quarter earnings are likely to have benefited from higher premiums, driven by the expansion of its commercial membership base.
Company News for Jul 5, 2024
by Zacks Equity Research
Companies In The News Are: STZ, PARA, HUM, MSFT.
Humana (HUM) Ties Up With PsychArmor for Better Veteran Care
by Zacks Equity Research
Humana's (HUM) subsidiaries team up with PsychArmor to enhance veteran care, offering specialized training at 23 senior primary care centers in Texas, thereby attracting more members of the targeted community to the centers.
UnitedHealth (UNH) Stock Drops 8% YTD: Should You Hold or Fold?
by Kaibalya Pravo Dey
As commercial business improves within the industry, UnitedHealth (UNH), with its diverse portfolio of offerings, is well-positioned to capitalize on the rising demand.
Humana's (HUM) CenterWell Expands in Louisiana With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell unit is likely to benefit from the opening of four new centers in the Baton Rouge and New Orleans areas in Louisiana, thus enhancing healthcare access for local seniors.
Humana's (HUM) CenterWell Sets Foot in Asheville With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell Senior Primary Care announces the opening of two centers in Asheville, thus enhancing access to high-quality healthcare services and driving revenues of the CenterWell unit.
Humana (HUM) Partners With UAB to Boost Care for MA Members
by Zacks Equity Research
Humana (HUM) expands its Medicare Advantage network in Alabama through a new partnership with UAB Health System, offering greater access to enhanced healthcare services.
Do Options Traders Know Something About Humana (HUM) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Humana (HUM) stock based on the movements in the options market lately.
Why Is Humana (HUM) Up 13.1% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Centene and Humana
by Zacks Equity Research
UnitedHealth, The Cigna, Centene and Humana have been highlighted in this Industry Outlook article.
Ensign Group (ENSG) Stock Down 2.4% Despite Q1 Earnings Beat
by Zacks Equity Research
Ensign Group (ENSG) expects revenues between $4.13 and $4.17 billion, the mid-point of which indicates an improvement of 11.3% from the 2023 figure.
4 HMO Stocks to Watch Amid Persistent Industry Challenges
by Debasmita Chatterjee
The Medical-HMO industry continues to witness an expanding customer base resulting from contract wins. However, high technology expenses and a shortage of medical personnel are a concern. UNH, CI, CNC and HUM are likely to navigate industry storms.
Cigna (CI) Q1 Earnings Beat on Client Wins in Evernorth Unit
by Zacks Equity Research
Cigna's (CI) Q1 results reflect strong organic growth in the Evernorth Health Services unit. It expects adjusted EPS of at least $28.40 for 2024, up from the earlier guidance of at least $28.25.